海尔生物获第十四届金融界“金智奖”杰出成长性企业

Core Insights - The "Qihang·2025 Financial Summit" held on December 26 in Beijing focused on "New Starting Point, New Momentum, New Journey," gathering hundreds of leaders and guests from regulatory bodies, industry associations, financial institutions, listed companies, and media [1] - The 14th "Jinzhi Award" results were announced, with Qingdao Haier Biomedical Co., Ltd. winning the "Outstanding Growth Enterprise" award, aimed at setting high-quality development benchmarks [1][3] - The award evaluation emphasized high-quality development across six dimensions: social responsibility, industrial contribution, investment returns, growth prospects, innovation efficiency, and outstanding brand [1] Company Highlights - The "Outstanding Growth Enterprise" award focuses on companies with sustainable growth potential and core competitiveness, encouraging deep engagement in niche markets and strengthening core technological barriers [3] - Haier Biomedical leverages technology innovation as a digital solution provider, enhancing industry intelligence through AI and automation [3] - The company employs a "co-creation" model to rapidly transform real needs from clinical and research fronts into scalable intelligent solutions, achieving significant efficiency improvements in various key scenarios [3] Financial Performance - By the first three quarters of 2025, revenue from new industries such as smart medication and blood technology accounted for 48% of Haier Biomedical's total revenue, with overseas market revenue increasing by 20.18% year-on-year, showcasing strong growth resilience and potential [4] - The company is effectively capitalizing on the domestic substitution trend, with increasing penetration and acceptance in research and medical markets [4] - Haier Biomedical's innovative technologies and products have served over 80 countries involved in the Belt and Road Initiative, enhancing its international reputation and brand credibility [4]